Grannus Therapeutics

Indianapolis, IN

Contact: John Fogelsong, CEO

Grannus is an early-stage oncology drug development company, with a unique approach to a well-validated target, the chaperone protein Hsp90, that has demonstrated efficacy in clinical studies but known limitations that have prevented previous drugs from being approved. By selectively targeting individual isoforms, or versions, of Hsp90, Grannus has overcome the limitations of the previous failed programs, and unlocked opportunity across multiple tumor types as a single therapy and in combination with other approved drugs.

Member Number: 201, Company

Member Since: 2023